Extrahepatic Islet Grafts With CD34+ Co-Transplantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for pancreatic islet transplantation, particularly in extrahepatic sites, suffer from poor engraftment and high islet cell death, limiting insulin independence and graft survival, especially in sites like the subcutaneous and intramuscular spaces.
Innovation Solution
Co-transplantation of insulin-producing cells with parathyroid gland-derived cells or CD34+ cells to enhance engraftment and survival, utilizing proangiogenic factors and hormones to promote vascularization and improve graft function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If pancreatic islets are transplanted into extrahepatic sites (subcutaneous or intramuscular space), then accessibility for implantation and removal is improved, but engraftment survival and insulin independence are worsened
Solution Approach 1:
The patent introduces a hydrogel matrix as an intermediary carrier that mimics the native pancreatic extracellular matrix. This hydrogel provides a supportive three-dimensional structure that promotes islet engraftment and survival in extrahepatic sites, acting as a bridge between the islets and the host tissue to enhance integration and function while maintaining accessibility.
2Reliability
If pancreatic islets are transplanted into the liver via portal vein infusion, then insulin independence is achieved, but islet survival is compromised
Solution Approach 1:
The patent applies preliminary action by pre-coating the islet transplantation catheter with a protective hydrogel layer before infusion. This pre-applied coating protects islets from mechanical stress and immune attack during transit through the portal vein, ensuring higher survival rates upon reaching the liver while maintaining the ability to achieve insulin independence.
3Object-affected harmful factors
If islets are encapsulated in devices to ensure safety, then immunosuppression may be eliminated, but blood supply to the graft is reduced
Solution Approach 1:
The patent employs a porous hydrogel matrix with controlled pore sizes that allows selective permeability. The porous structure permits diffusion of nutrients, oxygen, and insulin while providing a protective barrier against immune cells. This maintains blood supply and metabolic support to the graft while ensuring safety and potentially eliminating the need for immunosuppression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The co-transplantation method achieves improved survival and functional engraftment of insulin-producing cells in extrahepatic spaces, reversing diabetes in mouse models by enhancing vascularization and reducing islet cell death.
Implementation Method 1
co-transplantation of insulin-producing cells with parathyroid gland-derived cells or CD34+ cells to enhance engraftment and survival, utilizing proangiogenic factors and hormones to promote vascularization
Data Source
AI summary
Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.